Mercer Global Advisors’s Genmab GMAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$699K Sell
26,061
-467
-2% -$14K ﹤0.01% 1763
2025
Q4
$817K Sell
26,528
-2,001
-7% -$62.4K ﹤0.01% 1568
2025
Q3
$875K Sell
28,529
-3,938
-12% -$96K ﹤0.01% 1450
2025
Q2
$671K Sell
32,467
-17,692
-35% -$363K ﹤0.01% 1410
2025
Q1
$982K Buy
50,159
+29,316
+141% +$615K ﹤0.01% 1158
2024
Q4
$435K Sell
20,843
-4,804
-19% -$106K ﹤0.01% 1523
2024
Q3
$619K Sell
25,647
-277
-1% -$7.41K ﹤0.01% 1227
2024
Q2
$651K Sell
25,924
-3,339
-11% -$94.7K ﹤0.01% 1163
2024
Q1
$875K Sell
29,263
-16,449
-36% -$483K ﹤0.01% 1026
2023
Q4
$1.46M Sell
45,712
-9,952
-18% -$312K ﹤0.01% 836
2023
Q3
$1.96M Buy
55,664
+1,171
+2% +$44.6K 0.01% 709
2023
Q2
$2.07M Buy
54,493
+3,164
+6% +$126K 0.01% 719
2023
Q1
$1.94M Sell
51,329
-4,244
-8% -$163K 0.01% 690
2022
Q4
$2.35M Buy
55,573
+172
+0.3% +$7.09K 0.01% 651
2022
Q3
$1.78M Buy
55,401
+828
+2% +$29.1K 0.01% 653
2022
Q2
$1.77M Sell
54,573
-18,021
-25% -$584K 0.01% 644
2022
Q1
$2.63M Sell
72,594
-28,914
-28% -$992K 0.02% 567
2021
Q4
$4.02M Sell
101,508
-12,733
-11% -$531K 0.02% 424
2021
Q3
$4.99M Sell
114,241
-24,062
-17% -$1.08M 0.03% 352
2021
Q2
$5.65M Sell
138,303
-20,926
-13% -$808K 0.04% 309
2021
Q1
$5.23M Buy
159,229
+19,323
+14% +$727K 0.05% 291
2020
Q4
$5.69M Buy
139,906
+50,204
+56% +$1.88M 0.07% 208
2020
Q3
$3.28M Buy
89,702
+49,111
+121% +$1.78M 0.05% 276
2020
Q2
$1.38M Buy
40,591
+21,699
+115% +$591K 0.03% 411
2020
Q1
$400K Buy
+18,892
New +$421K 0.01% 728

Other funds holding GMAB

Mercer Global Advisors's GMAB Position: Q1 2026 in Review

Mercer Global Advisors reduced its Genmab (GMAB) stake by 1.8% in Q1 2026, selling an estimated $14K and leaving 26,061 shares worth $699K. The position accounts for ﹤0.01% of the portfolio, ranked #1763.

Mercer Global Advisors first reported a position in GMAB in Q1 2020 and has held it in 25 quarters since. The position peaked at $5.69M in Q4 2020. 272 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

  • Mercer Global Advisors held 26,061 shares of Genmab worth $699K as of Q1 2026.
  • Mercer Global Advisors sold 467 Genmab shares in Q1 2026, an estimated $14K.
  • Genmab made up ﹤0.01% of Mercer Global Advisors's portfolio in Q1 2026, its #1763 holding.
  • Mercer Global Advisors first reported a position in Genmab in Q1 2020 and has held it in 25 quarters since.
  • Mercer Global Advisors's Genmab position peaked at $5.69M in Q4 2020.
  • 272 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on Mercer Global Advisors's 13F filing for Q1 2026, filed 15 May 2026.